Metric Finance
LearnFAQ
LearnFAQ

Learn / MBX

NASDAQ: MBX

MBX Biosciences (MBX) stock, explained like you're 5

MBX Biosciences trades on the Nasdaq under the ticker MBX. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 2.6 billion dollars.

Ticker
MBX
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Mid cap, about 2.6 billion dollars

Is MBX Biosciences a small, medium or large cap company?

No. MBX Biosciences is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2.6 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How MBX Biosciences makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves MBX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Learn Why The Bull Case For MBX Biosciences Stock Could Change Following Early Obesity Data (Simply Wall Street)
  • (MBX) and the Role of Price Sensitive Allocations (Stock Traders Daily)
  • MBX Biosciences to Participate in Upcoming November Investor Conferences (Yahoo Finance)
  • MBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Average Price Target of $83.89 (MarketBeat)
  • Analysts Offer Insights on NA Companies: X Energy, Inc. Class A (XE) and MBX Biosciences, Inc. (MBX) (The Globe and Mail)

Follow MBX in your daily brief

Each trading day at 5 PM ET we post what happened to MBX Biosciences and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow MBX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about MBX Biosciences stock

What does MBX Biosciences do?

MBX Biosciences trades on the Nasdaq under the ticker MBX. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 2.6 billion dollars.

What is the ticker symbol for MBX Biosciences?

MBX Biosciences trades under the ticker MBX on the Nasdaq.

What is MBX Biosciences's market cap?

MBX Biosciences is a mid cap stock with a market cap of about 2.6 billion dollars.

How does MBX Biosciences make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves MBX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow MBX stock every day?

Add MBX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow MBX daily

A free brief on MBX Biosciences and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare MBX: MBX vs NVS, MBX vs AZN, MBX vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed